Animal models for retinitis pigmentosa induced by MNU; disease progression, mechanisms and therapeutic trials - PubMed

Review

Animal models for retinitis pigmentosa induced by MNU; disease progression, mechanisms and therapeutic trials

A Tsubura et al. Histol Histopathol. 2010 Jul.

Abstract

Retinitis pigmentosa (RP) is a group of inherited neurodegenerative diseases in humans characterized by loss of photoreceptor cells leading to visual disturbance and eventually to blindness. A single systemic administration of N-methyl-N-nitrosourea (MNU) causes retinal degeneration in various animal species. The retinal degeneration is highly reproducible, and the photoreceptor cell loss occurs within seven days after MNU administration via apoptosis resembling human RP. Here, we describe the disease progression, disease mechanisms, and therapeutic trials of MNU-induced retinal degeneration.

Similar articles

• [Characteristics of N-methyl-N-nitrosourea-induced retinal degeneration in animals and application for the therapy of human retinitis pigmentosa].

  Yoshizawa K, Tsubura A. Yoshizawa K, et al. Nippon Ganka Gakkai Zasshi. 2005 Jun;109(6):327-37. Nippon Ganka Gakkai Zasshi. 2005. PMID: 16047940 Review. Japanese.

• The temporal topography of the N-Methyl- N-nitrosourea induced photoreceptor degeneration in mouse retina.

  Tao Y, Chen T, Fang W, Peng G, Wang L, Qin L, Liu B, Fei Huang Y. Tao Y, et al. Sci Rep. 2015 Dec 21;5:18612. doi: 10.1038/srep18612. Sci Rep. 2015. PMID: 26685797 Free PMC article.

• Nicotinamide prevents N-methyl-N-nitrosourea-induced photoreceptor cell apoptosis in Sprague-Dawley rats and C57BL mice.

  Kiuchi K, Yoshizawa K, Shikata N, Matsumura M, Tsubura A. Kiuchi K, et al. Exp Eye Res. 2002 Mar;74(3):383-92. doi: 10.1006/exer.2001.1127. Exp Eye Res. 2002. PMID: 12014919

• Curcumin suppresses N-methyl-N-nitrosourea-induced photoreceptor apoptosis in Sprague-Dawley rats.

  Emoto Y, Yoshizawa K, Uehara N, Kinoshita Y, Yuri T, Shikata N, Tsubura A. Emoto Y, et al. In Vivo. 2013 Sep-Oct;27(5):583-90. In Vivo. 2013. PMID: 23988891

• Review: Animal models of N-Methyl-N-nitrosourea-induced mammary cancer and retinal degeneration with special emphasis on therapeutic trials.

  Tsubura A, Lai YC, Miki H, Sasaki T, Uehara N, Yuri T, Yoshizawa K. Tsubura A, et al. In Vivo. 2011 Jan-Feb;25(1):11-22. In Vivo. 2011. PMID: 21282729 Review.

Cited by

• Epigallocatechin Gallate Slows Retinal Degeneration, Reduces Oxidative Damage, and Modifies Circadian Rhythms in P23H Rats.

  Perdices L, Fuentes-Broto L, Segura F, Cuenca N, Orduna-Hospital E, Pinilla I. Perdices L, et al. Antioxidants (Basel). 2020 Aug 8;9(8):718. doi: 10.3390/antiox9080718. Antioxidants (Basel). 2020. PMID: 32784376 Free PMC article.

• Optimized nonionic emulsifier for the efficient delivery of astaxanthin nanodispersions to retina: in vivo and ex vivo evaluations.

  Xu L, Yu H, Sun H, Yu X, Tao Y. Xu L, et al. Drug Deliv. 2019 Dec;26(1):1222-1234. doi: 10.1080/10717544.2019.1682718. Drug Deliv. 2019. PMID: 31747793 Free PMC article.

• Adeno-associated virus-mediated neuroglobin overexpression ameliorates the N-methyl-N-nitrosourea-induced retinal impairments: a novel therapeutic strategy against photoreceptor degeneration.

  Tao Y, Yang Z, Fang W, Ma Z, Huang YF, Li Z. Tao Y, et al. Ther Clin Risk Manag. 2017 Oct 13;13:1379-1389. doi: 10.2147/TCRM.S144822. eCollection 2017. Ther Clin Risk Manag. 2017. PMID: 29075122 Free PMC article.

• Hyperglycemia-independent neonatal streptozotocin-induced retinopathy (NSIR) in rats.

  Lin Y, Du W, Fu X, Huang L, Hong Y, Tan H, Xiao L, Ren X, Wang Y, Chen D. Lin Y, et al. Front Pharmacol. 2024 Jul 23;15:1395887. doi: 10.3389/fphar.2024.1395887. eCollection 2024. Front Pharmacol. 2024. PMID: 39108749 Free PMC article.

• Protective Effect of Salvianolic Acid A against N-Methyl-N-Nitrosourea-Induced Retinal Degeneration.

  Zhou Y, Xu W, Liu A, Tao Y, Wang Q, Yang Y, Wang L, Huang Y. Zhou Y, et al. Evid Based Complement Alternat Med. 2022 May 27;2022:1219789. doi: 10.1155/2022/1219789. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35668785 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Sercrisma International S.L.

• Other Literature Sources

  • The Lens - Patent Citations Database